Cara Therapeutics Stock - Acciones de Cara Therapeutics

5.06 0 (—)

Data as of 24 March 2023

Analyst Rating

Date	Research Firm	Último Cambio	Current	Target
8/03/23	B of A Securities	Downgrades	Underperform	$6.00
7/03/23	JP Morgan	Maintains	Overweight	$16.00
7/03/23	Canaccord Genuity	Maintains	Buy	$25.00

Q4 2022	EST	Actual	Surprise
EPS:	-0.320	-0.560	-0.2400
Rev:	$16.25M	$821.00K	-$12.99M

Q3 2022	EST	Actual	Surprise
EPS:	-0.420	-0.430	-0.0100
Rev:	$9.83M	$20.27M	$983.00K

Q2 2022	EST	Actual	Surprise
EPS:	-0.250	-0.080	0.1700
Rev:	$20.71M	—	$2.29M